1,321 results match your criteria Lennox-Gastaut Syndrome


Dexmedetomidine for Electrocorticography in Patients With Lennox-Gastaut Syndrome Presenting for Epilepsy Surgery: A Case Report.

A A Pract 2019 Apr 17. Epub 2019 Apr 17.

From the Division of Neuroanesthesia, Department of Anaesthesiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India.

We report the anesthetic management of 2 patients with Lennox-Gastaut syndrome presenting for respective epilepsy surgery with intraoperative electrocorticography. Electrocorticography is a useful tool to guide the localization of the epileptogenic focus for surgical resection in epilepsy surgery. Drug interactions, proconvulsant or anticonvulsant activity of the anesthetics, and anesthetic influence on intraoperative electrocorticography are the primary concerns to be addressed in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1213/XAA.0000000000001020DOI Listing
April 2019
1 Read

Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.

Authors:
M Scott Perry

Epilepsy Curr 2019 Mar-Apr;19(2):93-95

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome Devinsky O, Patel AD, Cross JH, et al; GWPCARE3 Study Group. N Engl J Med. 2018;378:1888-1897. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1535759719835671DOI Listing
April 2019
7 Reads

Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

Drugs Today (Barc) 2019 Mar;55(3):177-196

Department of Neuroscience, Biomedicine and Movement Science, University of Verona, Verona, Italy; Division of Neurology, "Franz Tappeiner" Hospital, Merano, Bolzano, Italy.

Epilepsy is one of the most common chronic disorders of the brain affecting around 70 million people worldwide. Treatment is mainly symptomatic, and most patients achieve long-term seizure control. Up to one-third of the affected subjects, however, are resistant to anticonvulsant therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2019.55.3.2909248DOI Listing
March 2019
2 Reads

Evaluation of the Effects of Clobazam on Seizure Control and Quality of Life in Children With Lennox-Gastaut Syndrome: A Pilot Study.

J Child Neurol 2019 Mar 27:883073819836534. Epub 2019 Mar 27.

2 Department of Neurology, Jacobs School of Medicine at the University at Buffalo, Buffalo, NY, USA.

Purpose:: This is a prospective study of children with Lennox-Gastaut syndrome receiving clobazam as adjunctive therapy. This pilot study aims to examine medication effectiveness as it relates to seizure reduction, as well as improvement in parent-reported behavior and quality of life (QOL).

Methods:: Ten patients with Lennox-Gastaut syndrome aged 3-11 years were enrolled in this 6-week, 4 phase study. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0883073819836534
Publisher Site
http://dx.doi.org/10.1177/0883073819836534DOI Listing
March 2019
9 Reads

Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders.

Lancet Neurol 2019 May 22;18(5):504-512. Epub 2019 Mar 22.

Department of Medicine, Campus Bio-Medico, University of Rome, Rome, Italy; European Center for Brain Research and IRCCS Santa Lucia Foundation, Rome, Italy.

In the past two decades, there has been an increasing interest in the therapeutic potential of cannabinoids for neurological disorders such as epilepsy, multiple sclerosis, pain, and neurodegenerative diseases. Cannabis-based treatments for pain and spasticity in patients with multiple sclerosis have been approved in some countries. Randomised controlled trials of plant-derived cannabidiol for treatment of Lennox-Gastaut syndrome and Dravet syndrome, two severe childhood-onset epilepsies, provide evidence of anti-seizure effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(19)30032-8DOI Listing
May 2019
2 Reads

Industry update covering November 2018.

Authors:
Elaine Harris

Ther Deliv 2019 Mar;10(3):143-150

Innovation21 Ltd, Unit B, Deansgrange Business Park, Blackrock, Co Dublin, Ireland.

November 2018, the period covered by this article, showed strong activity in mergers/acquisitions and collaborations, including the announcement of a deal for the global manufacture of a micellar nanoparticulate formulation of paclitaxel. The month also brought positive clinical trial news in therapeutic areas such as pancreatic cancer using CAR-T therapies and asthma. In regulatory news, the US FDA issued a warning highlighting concerns about the serious complications that can occur when using unapproved painkillers with implantable drug pumps and approval was announced for an oral film formulation to treat Lennox-Gastaut syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4155/tde-2019-0002DOI Listing
March 2019
2 Reads

Development of a classifier to identify patients with probable Lennox-Gastaut syndrome in health insurance claims databases via random forest methodology.

Curr Med Res Opin 2019 Mar 14. Epub 2019 Mar 14.

e Lundbeck , Deerfield , IL , USA.

Objective: Describe the development of a claims-based classifier utilizing machine learning to identify patients with probable Lennox-Gastaut syndrome (LGS) from 6 state Medicaid programs.

Methods: Patients were included if they had ≥2 medical claims ≥30 days apart for specified or unspecified epilepsy, excluding those with ≥1 claim for petit mal status. The LGS classifier utilized a random forest algorithm, a compilation of thousands of binary decision trees in which machine-generated predictor variables split the data set into branches that predict the presence or absence of LGS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03007995.2019.1595552DOI Listing
March 2019
3 Reads

The direct cost of seizure events in severe childhood-onset epilepsies: A retrospective claims-based analysis.

Epilepsy Behav 2019 Mar 1;93:65-72. Epub 2019 Mar 1.

Greenwich Biosciences, Inc., Carlsbad, CA, USA.

Objective: The objective of the study was to assess the direct cost of medically treated seizure events in severe childhood-onset epilepsies. Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC) are representative conditions associated with frequent intractable seizures.

Methods: Commercial and Medicaid insurance claims from 2010 to 2015 were queried to identify patients with possible LGS, possible DS, or TSC, having ≥2 years of continuous insurance from the date of first epilepsy/seizure diagnosis or antiepileptic drug (AED) fill (index date). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yebeh.2019.01.045DOI Listing
March 2019
4 Reads

How often is antiseizure drug-free ketogenic diet therapy achieved?

Epilepsy Behav 2019 Mar 1;93:29-31. Epub 2019 Mar 1.

Department of Pediatrics, The Johns Hopkins Hospital, Baltimore, MD, USA; Department of Neurology, The Johns Hopkins Hospital, Baltimore, MD, USA. Electronic address:

The ketogenic diet (KD) is often started not only for seizure reduction but also to potentially wean antiseizure drugs (ASDs) in children with epilepsy. Although there have been several publications regarding ASD reduction on the KD, it is unknown how often complete medication withdrawal occurs. We reviewed the charts of all children started on the KD at Johns Hopkins Hospital and Johns Hopkins All Children's Hospital from 1/11 to 4/18. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yebeh.2019.01.042DOI Listing
March 2019
1 Read

What is the role of cannabidiol in refractory epilepsy?

JAAPA 2019 Mar;32(3):16-18

At the time this article was written, Kathryn M. LaFleur was a student in the PA program at Sacred Heart University in Fairfield, Conn. Eric C. Nemec II is director of research and assessment and a clinical associate professor in the PA program at Sacred Heart University. The authors have disclosed no potential conflicts of interest, financial or otherwise.

The FDA recently approved the first cannabidiol oral medication to treat refractory epilepsy in patients with Dravet syndrome and Lennox-Gastaut syndrome. This article describes the safety and efficacy of cannabidiol treatment in patients with refractory epilepsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.JAA.0000553393.36249.dfDOI Listing
March 2019
1 Read

Tonic status epilepticus in a centenarian woman.

Epileptic Disord 2019 Feb;21(1):92-96

Department of Neurology, Marqués de Valdecilla University Hospital, Santander, Spain.

Generalized tonic status epilepticus (TSE) is a rare epileptic condition. It occurs usually in the context of symptomatic generalized epilepsy, in particular, in subjects with a diagnosis of Lennox-Gastaut syndrome, atypical forms of idiopathic (genetic) generalized epilepsy, or as a paradoxical effect during treatment with diverse antiepileptic drugs. Herein, we describe the case of an elderly woman on chronic treatment with psychotropic drugs who developed an episode of generalized TSE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/epd.2019.1031DOI Listing
February 2019
7 Reads

Quinidine Therapy for Lennox-Gastaut Syndrome With Mutation. A Case Report and Literature Review.

Front Neurol 2019 5;10:64. Epub 2019 Feb 5.

Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.

Mutations in the Potassium channel subfamily T member 1 () gene have been reported in a range of epileptic encephalopathies. Here we report the case of a 12-year-old male suffering from multiple types of epileptic seizures and cognitive decline from the age of 10. The patient had four types of epileptic seizures, including tonic seizures, atypical absence seizures, myoclonic seizures, and generalized tonic-clonic seizures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2019.00064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370615PMC
February 2019
2 Reads

Forced normalization after turning off vagus nerve stimulation in Lennox-Gastaut syndrome.

Epilepsy Behav Case Rep 2019 27;11:81-83. Epub 2019 Jan 27.

Division of Neurology, Department of Medicine, University of Saskatchewan, Saskatoon, Canada.

Forced normalization is the development of psychiatric symptoms in a patient experiencing remission of seizures. We present a case of Lennox Gastaut syndrome in which forced normalization developed after vagus nerve stimulation was stopped. The patient had drug resistant epilepsy and failed anti-seizure drugs, vagus nerve stimulation, and a partial callosotomy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22133232183017
Publisher Site
http://dx.doi.org/10.1016/j.ebcr.2019.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369242PMC
January 2019
10 Reads

Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.

Epilepsia 2019 Mar 11;60(3):419-428. Epub 2019 Feb 11.

GW Research Ltd, Cambridge, UK.

Objective: Patients with Lennox-Gastaut syndrome (LGS) who completed 1 of 2 randomized, double-blind, placebo-controlled trials of add-on cannabidiol (CBD) (GWPCARE3, NCT02224560 or GWPCARE4, NCT02224690) were invited to enroll in an open-label extension (OLE) study evaluating the long-term safety and efficacy of CBD (GWPCARE5, NCT02224573). Herein we present an interim analysis of the safety, efficacy, and patient-reported outcomes from this trial.

Methods: Patients received a pharmaceutical formulation of highly purified CBD oral solution (Epidiolex; 100 mg/mL), titrated from 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/epi.14670DOI Listing
March 2019
2 Reads

Cannabidiol (Epidiolex) for epilepsy.

Authors:

Med Lett Drugs Ther 2018 Nov;60(1559):182-184

View Article

Download full-text PDF

Source
November 2018
1 Read

Gene mutations in paediatric epilepsies cause NMDA-pathy, and phasic and tonic GABA-pathy.

Dev Med Child Neurol 2019 Jan 25. Epub 2019 Jan 25.

Inserm U1129, Infantile Epilepsies and Brain Plasticity, CEA Gif/Yvette, Pôle de Recherche et d'Enseignement Supérieur Sorbonne Paris Cité, Paris Descartes University, Paris, France.

The aim of this study was to disentangle mechanisms of epileptogenesis in monogenic epilepsies in children. We reviewed paediatric monogenic epilepsies excluding brain malformation or an inborn error of metabolism, but including the gene function whether there is loss-of-function or gain-of-function, age at gene expression when available, and associated epilepsy syndrome. Genes for which at least five patients with similar epilepsy phenotype had been reported were selected. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/dmcn.14152
Publisher Site
http://dx.doi.org/10.1111/dmcn.14152DOI Listing
January 2019
10 Reads

[Cannabis and cannabinoids-easier access, hype and disappointment : What has been confirmed in therapy?]

Internist (Berl) 2019 Mar;60(3):309-314

Zentrum für Seltene Erkrankungen (ZSEB), Universitätsklinikum Bonn, 53127, Bonn, Deutschland.

Background: Cannabis products are being increasingly liberalized all over the world and there is a huge interest in cannabis-based medicine.

Objectives: Presentation of current studies on the efficacy of different cannabis-based medicine for the treatment of various diseases CURRENT DATA: In German pharmaceutical legislation, nabiximols is approved for the treatment of moderate to severe therapy-resistant spasticity in multiple sclerosis and nabilone is approved for the treatment of therapy-resistant chemotherapy-associated nausea and vomiting. In case of therapy failure cannabinoids, as part of an individual therapeutic attempt, may be considered for the treatment of chronic pain (neuropathic pain, cancer pain, non-neuropathic noncancer pain), cachexia in human immunodeficiency virus as well as for Dravet and Lennox-Gastaut syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00108-019-0556-0DOI Listing
March 2019
2 Reads

Cannabinoid therapy in epilepsy.

Curr Opin Neurol 2019 Apr;32(2):220-226

Division of Child Neurology, Children's Hospital of Philadelphia.

Purpose Of Review: To review the history, pharmacology, and clinical science of cannabidiol (CBD) in the treatment of epilepsy.

Recent Findings: Phase III randomized controlled trials and prospective open label trials have provided efficacy and safety data for the use of CBD in pediatric onset severe epilepsies. The product that was studied in the vast majority of these published trials, Epidiolex (>99% of CBD and <0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WCO.0000000000000660DOI Listing
April 2019
1 Read

Factors affecting epilepsy prognosis in patients with tuberous sclerosis.

Childs Nerv Syst 2019 Mar 23;35(3):463-468. Epub 2019 Jan 23.

Department of Biostatistics, Cukurova University, Adana, Turkey.

Purpose: We aimed to determine the characteristics of epileptic seizures that significantly affect the cognitive functions of 83 patients followed with tuberous sclerosis complex (TSC), their resistance to treatment and risk factors causing this resistance.

Materials-methods: In order to determine the prognosis, the seizure-free/seizure-controlled group and the group with refractory seizures were compared. In addition, risk factors affecting cognitive functions in the patients were determined. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00381-019-04066-7
Publisher Site
http://dx.doi.org/10.1007/s00381-019-04066-7DOI Listing
March 2019
11 Reads

Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.

Ann Pharmacother 2019 Jun 8;53(6):603-611. Epub 2019 Jan 8.

1 University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.

Objective: To review the efficacy, safety, pharmacology and pharmacokinetics of pure, plant-derived cannabidiol (CBD; Epidiolex) in the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).

Data Sources: Relevant information was identified through EMBASE and Ovid MEDLINE (1946 to October 2018). Product labeling and https://www. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018822124DOI Listing
June 2019
1 Read

Late-onset Lennox-Gastaut syndrome: Diagnostic evaluation and outcome.

Neurol Clin Pract 2018 Oct;8(5):397-402

Department of Neurology, Mayo Clinic, Rochester, MN.

Background: We describe the clinical features and outcome in patients with late-onset Lennox-Gastaut syndrome (LGS).

Methods: Adult patients evaluated between January 1, 2000, and March 1, 2017, who presented with onset of LGS ≥10 years were identified. Data abstracted included age at seizure onset, seizure types, etiology, treatments, EEG and neuroimaging results, cerebrospinal fluid (CSF) findings, and autoimmune evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/CPJ.0000000000000527DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276343PMC
October 2018
2 Reads

Lennox-Gastaut Syndrome in Mitochondrial Disease.

Yonsei Med J 2019 Jan;60(1):106-114

Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.

Purpose: Previous studies have shown that neurologic symptoms are dominant in patients with mitochondrial diseases, and most of these patients have seizure-related disorders. The epileptic classification of these patients as Lennox-Gastaut syndrome (LGS) is as high as 25%. This study aimed to investigate the clinical manifestations, diagnoses, treatments, and epilepsy in LGS, which is associated with mitochondrial disease. Read More

View Article

Download full-text PDF

Source
https://synapse.koreamed.org/DOIx.php?id=10.3349/ymj.2019.60
Publisher Site
http://dx.doi.org/10.3349/ymj.2019.60.1.106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298891PMC
January 2019
16 Reads

Spectrum and time course of epilepsy and the associated cognitive decline in duplication syndrome.

Neurology 2019 Jan 14;92(2):e108-e114. Epub 2018 Dec 14.

From the Departments of Neurology (D.M., B.S., R.S., D.G., V.N.P., A.M.G.) and Pediatrics (R.S., D.G.), Baylor College of Medicine, Houston, TX.

Objective: We characterized the epilepsy features and contribution to cognitive regression in 47 patients with duplication syndrome (MDS) and reviewed these characteristics in over 280 MDS published cases.

Methods: The institutional review board approved this retrospective review of medical records and case histories of patients with MDS.

Results: The average age at enrollment was 10 ± 7 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006742DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340341PMC
January 2019
3 Reads

The refractory epilepsy screening tool for Lennox-Gastaut syndrome (REST-LGS).

Epilepsy Behav 2019 Jan 8;90:148-153. Epub 2018 Dec 8.

Icahn School of Medicine at Mount Sinai Health Systems, 10 Union Square East, Suite 5G, New York, NY 10003, USA. Electronic address:

Background: The complex clinical presentation and progression of Lennox-Gastaut syndrome (LGS) can complicate the accurate diagnosis of this severe, lifelong, childhood-onset epilepsy, often resulting in suboptimal treatment. The Refractory Epilepsy Screening Tool for LGS (REST-LGS) was developed to improve the identification of patients with LGS.

Methods: Using the Modified Delphi Consensus, a group of experts developed and tested the REST-LGS Case Report Form (CRF) comprising 8 criteria (4 major, 4 minor) considered potentially indicative of LGS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yebeh.2018.11.016DOI Listing
January 2019
14 Reads

Evaluation of WO2014121383 A1: a process for preparation of rufinamide and intermediates.

Expert Opin Ther Pat 2019 Jan 19;29(1):7-10. Epub 2018 Nov 19.

a Department of Chemistry , School of Advanced Sciences, Vellore Institute of Technology , Vellore , India.

Introduction: There is great potential in the synthetic development of rufinamide to treat childhood-onset epilepsy known as Lennox-Gastaut syndrome (LGS). Areas covered: 1,4-disubstituted triazole ring formed by 1,3-dipolar cycloaddition reaction is an important structural motif widely used to construct diverse chemotypes in chemical, biological, and material fields. 1,2,3-triazole ring containing rufinamide, an antiepileptic drug developed by Novartis, is useful in combination with other antiepileptic medicaments for the treatment of childhood-onset epilepsy known as LGS. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13543776.2019.1
Publisher Site
http://dx.doi.org/10.1080/13543776.2019.1549230DOI Listing
January 2019
2 Reads
4.297 Impact Factor

What is the interest of the electroencephalogram in the syndromic diagnosis?

Tunis Med 2018 Aug - Sep;96(8-09):528-531

Introduction: The identification of the epileptic syndrome is a challenge particularly in childhood epilepsies. In fact, the diagnosis may need several years to be fulfilled.

Observation: Our patient presented at the age of 3 years 6 months atypical absence. Read More

View Article

Download full-text PDF

Source
November 2018
31 Reads

Lennox-Gastaut Syndrome: In a Nutshell.

Cureus 2018 Aug 13;10(8):e3134. Epub 2018 Aug 13.

Internal Medicine, Punjab Medical College Allied Hospital Faisalabad, Faisalabad, PAK.

Lennox-Gastaut syndrome is one of the rare childhood-onset epileptic encephalopathies, characterized by multiple type seizure disorder, the typical pattern on electroencephalogram and intellectual disability. Tonic-type seizures are most commonly seen in these patients. Behavioral disturbances and cognitive decline are gradual-onset and last long after the first episode of epileptiform activity. Read More

View Article

Download full-text PDF

Source
https://www.cureus.com/articles/14127-lennox-gastaut-syndrom
Publisher Site
http://dx.doi.org/10.7759/cureus.3134DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207167PMC
August 2018
25 Reads

[Ten years' experience with vagus nerve stimulation in a paediatric population].

Rev Neurol 2018 Nov;67(10):382-386

Hospital Infantil Universitario Nino Jesus, 28009 Madrid, Espana.

Introduction: Fifty million people are affected by epilepsy. Up to 30% are not controlled with the aid of antiepileptic drugs. The vagus nerve stimulator (VNS) is a therapeutic alternative that must be taken into account. Read More

View Article

Download full-text PDF

Source
November 2018
16 Reads

Efficacy of cannabinoids in paediatric epilepsy.

Dev Med Child Neurol 2019 01 6;61(1):13-18. Epub 2018 Nov 6.

Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand.

There are hundreds of compounds found in the marijuana plant, each contributing differently to the antiepileptic and psychiatric effects. Cannabidiol (CBD) has the most evidence of antiepileptic efficacy and does not have the psychoactive effects of ∆ -tetrahydrocannabinol. CBD does not act via cannabinoid receptors and its antiepileptic mechanism of action is unknown. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/dmcn.14087
Publisher Site
http://dx.doi.org/10.1111/dmcn.14087DOI Listing
January 2019
18 Reads

The pharmacological management of Lennox-Gastaut syndrome and critical literature review.

Seizure 2018 Dec 26;63:17-25. Epub 2018 Oct 26.

Department of child Neuropsychiatry, Tor Vergata University of Rome, Rome, Italy. Electronic address:

Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy with a prevalence of 1-2% of all patients with epilepsy. It is characterized by multiple pharmaco-resistant seizure types, including tonic, atypical absences and tonic or atonic drop attacks, and the presence of electroencephalographic abnormalities, such as slow-spike waves and paroxysmal fast rhythms. Intellectual disability, behavioural and psychiatric disorders are common comorbidities; these disturbances have a multi-factorial pathogenesis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10591311183055
Publisher Site
http://dx.doi.org/10.1016/j.seizure.2018.10.016DOI Listing
December 2018
15 Reads
2.059 Impact Factor

Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.

Drugs 2018 Nov;78(17):1791-1804

Department of Experimental and Clinical Medicine, Neurological Clinic, Marche Polytechnic University, Via Conca 71, 60020, Ancona, Italy.

Background: Approximately one-third of patients with epilepsy presents seizures despite adequate treatment. Hence, there is the need to search for new therapeutic options. Cannabidiol (CBD) is a major chemical component of the resin of Cannabis sativa plant, most commonly known as marijuana. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-018-0992-5DOI Listing
November 2018
11 Reads

Medical Use of Cannabinoids.

Drugs 2018 Nov;78(16):1665-1703

Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Plaza Ramón y Cajal s/n, 28040 , Madrid, Spain.

Cannabinoid receptors, endocannabinoids and the enzymes responsible for their biosynthesis and degradation constitute the endocannabinoid system. In recent decades, the endocannabinoid system has attracted considerable interest as a potential therapeutic target in numerous pathological conditions. Its involvement in several physiological processes is well known, such as in energy balance, appetite stimulation, blood pressure, pain modulation, embryogenesis, nausea and vomiting control, memory, learning and immune response, among others, as well as in pathological conditions where it exerts a protective role in the development of certain disorders. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40265-018-0996-1
Publisher Site
http://dx.doi.org/10.1007/s40265-018-0996-1DOI Listing
November 2018
29 Reads

Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development.

Epilepsia 2018 10;59(10):1842-1866

Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, Washington.

The Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV) took place in Madrid, Spain, on May 13-16, 2018 and was attended by 168 delegates from 28 countries. The conference provided a forum for professionals involved in basic science, clinical research, regulatory affairs, and clinical care to meet and discuss the latest advances related to discovery and development of drugs and devices aimed at improving the management of people with epilepsy. This progress report provides a summary of findings on investigational compounds for which data from both preclinical studies and studies in patients were presented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/epi.14555DOI Listing
October 2018
18 Reads

Improved seizure control and regaining cognitive milestones after vagus nerve stimulation revision surgery in Lennox-Gastaut syndrome.

Epilepsy Behav Case Rep 2018 11;10:111-113. Epub 2018 Sep 11.

Department of Neurosurgery, Maastricht UMC +, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands.

We report a child with Lennox-Gastaut syndrome with an increase in seizure frequency and loss of psychomotor skills due to a disintegrated cervical VNS lead, not detected during standard device monitoring. The lead was completely removed and replaced by a new 303 lead on the same nerve segment. After reinitiating VNS, side effects forced us to switch it off, resulting in immediate seizure recurrence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebcr.2018.08.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197149PMC
September 2018
2 Reads

Pharmacokinetics of clobazam oral soluble film.

Epilepsia 2018 11 24;59(11):2153-2161. Epub 2018 Oct 24.

Aquestive Therapeutics, Inc, Warren, New Jersey.

Objective: Clobazam oral soluble film (COSF) is a novel dosage form under development for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. The present study was undertaken to assess the pharmacokinetics of clobazam administered as single doses of COSF 20 and 10 mg compared with clobazam tablets (CTAB) 20 and 10 mg in healthy adults. A secondary objective was to assess the safety and tolerability of single doses of COSF 20 and 10 mg. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/epi.14581DOI Listing
November 2018
6 Reads

A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects
.

Int J Clin Pharmacol Ther 2019 Jan;57(1):11-19

Objective: Phase I, open-label, randomized, single-dose, 3-period crossover study assessing pharmacokinetics (PK) and safety of ZX008, a liquid oral formulation of fenfluramine (FFA) under development for adjunctive treatment of Dravet syndrome and Lennox-Gastaut syndrome, administered with and without a combined antiepileptic drug (AED) regimen of stiripentol (STP), valproate (VPA), and clobazam (CLB) (STP regimen).

Materials And Methods: 26 healthy adults were administered the following treatments: ZX008 0.8 mg/kg; STP 3,500 mg, CLB 20 mg, VPA 25 mg/kg (max. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5414/CP203276DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298132PMC
January 2019
14 Reads

Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with Lennox-Gastaut syndrome: Final results from randomized study 303.

Eur J Paediatr Neurol 2019 Jan 27;23(1):126-135. Epub 2018 Sep 27.

Formerly of Eisai Neurology Business Group, Eisai Inc., 100 Tice Boulevard, Woodcliff Lake, NJ 07677, USA. Electronic address:

Objective: Evaluate the long-term safety, tolerability, and behavioral effects of adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with inadequately controlled seizures associated with Lennox-Gastaut syndrome (LGS).

Methods: Study 303 (ClinicalTrials.gov identifier NCT01405053) was a multicenter, randomized, open-label, Phase III trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpn.2018.09.010DOI Listing
January 2019
2 Reads
1.934 Impact Factor

Sulthiame add-on therapy in children with Lennox-Gastaut syndrome: A study of 44 patients.

Seizure 2018 Nov 27;62:55-58. Epub 2018 Sep 27.

Hospital de Pediatría A Fleming, Mendoza, Argentina.

Purpose: The aim of this study was to evaluate efficacy and tolerability of sulthiame as an add-on treatment in 44 patients with Lennox-Gastaut syndrome (LGS) refractory to other antiepileptic drugs and/or non-pharmacological treatment.

Methods: Patients were selected according to the following criteria: (1) age 4 years or older, (2) a diagnosis of LGS refractory to at least four previous antiepileptic drugs, alone or in combination. Neurologic examinations, brain magnetic resonance imaging, and repeated prolonged electroencephalography (EEG) or video-EEG studies were performed in all cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.seizure.2018.09.019DOI Listing
November 2018
12 Reads

Diagnosis switching and outcomes in a cohort of patients with potential epilepsy with myoclonic-atonic seizures.

Epilepsy Res 2018 11 24;147:95-101. Epub 2018 Sep 24.

Department of Pediatrics, Section of Neurology, Children's Hospital of Colorado, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address:

Introduction: There is overlap in the electroclinical features of many childhood epilepsy syndromes, especially those presenting with multiple seizure types, such as epilepsy with myoclonic-atonic seizures (EMAS) and Lennox-Gastaut syndrome (LGS). This study aimed to determine the frequency of diagnosis switching and the factors influencing epilepsy syndrome diagnosis in a cohort of children with possible EMAS, as well as to explore the relationship between epilepsy syndrome diagnoses, key electroclinical features, and clinically relevant outcomes.

Methods: This is a cross-sectional retrospective chart review of children treated at the Children's Hospital of Colorado with a potential diagnosis of EMAS. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09201211183040
Publisher Site
http://dx.doi.org/10.1016/j.eplepsyres.2018.09.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223641PMC
November 2018
4 Reads

A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam.

J Clin Pharmacol 2019 Jan 4;59(1):7-19. Epub 2018 Oct 4.

H. Lundbeck A/S, Valby, Denmark.

Clobazam (CLB) is a 1,5-benzodiazepine that has been widely used as an anxiolytic and antiseizure drug (ASD) since it was first synthesized over 50 years ago. CLB was approved in the United States in 2011 as adjunctive therapy for seizures in patients ≥2 years old with Lennox-Gastaut syndrome. CLB pharmacokinetics (PK) have been studied in single- and multiple-dose administrations in healthy subjects. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcph.1313
Publisher Site
http://dx.doi.org/10.1002/jcph.1313DOI Listing
January 2019
2 Reads

A Case of Lennox-Gastaut Syndrome in a 6-Year-Old Child with Moyamoya Disease.

J Neurosci Rural Pract 2018 Oct-Dec;9(4):658-659

Department of Neurology, Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.

View Article

Download full-text PDF

Source
http://www.ruralneuropractice.com/text.asp?2018/9/4/658/2398
Publisher Site
http://dx.doi.org/10.4103/jnrp.jnrp_85_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126310PMC
October 2018
9 Reads

Evolution and course of early life developmental encephalopathic epilepsies: Focus on Lennox-Gastaut syndrome.

Epilepsia 2018 11 26;59(11):2096-2105. Epub 2018 Sep 26.

Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut.

Objectives: Developmental encephalopathic epilepsies (DEEs) are characterized by refractory seizures, disability, and early death. Opportunities to improve care and outcomes focus on West syndrome/infantile spasms (WS/IS). Lennox-Gastaut syndrome (LGS) is almost as common but receives little attention. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/epi.14569
Publisher Site
http://dx.doi.org/10.1111/epi.14569DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215498PMC
November 2018
2 Reads

Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.

Epilepsy Behav 2018 11 18;88:66-73. Epub 2018 Sep 18.

Greenwich Biosciences, Inc., Carlsbad, CA, United States of America.

Objective: Lennox-Gastaut syndrome (LGS) is a severe and treatment-resistant epilepsy syndrome characterized by multiple subtypes of intractable seizures, moderate to severe cognitive impairment, and slow spike-wave complexes on electroencephalographic (EEG) recordings. Lennox-Gastaut syndrome is also associated with increased risk for injury, reduced quality of life, long-term disability, and early mortality. By evaluating private and public US medical insurance claims, we quantified healthcare utilization and direct costs in patients with possible LGS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yebeh.2018.08.032DOI Listing
November 2018
3 Reads

Vagal Nerve Stimulation: Indications for Revision in Adult Refractory Epilepsy.

World Neurosurg 2018 Dec 11;120:e1047-e1053. Epub 2018 Sep 11.

Allegheny General Hospital, Department of Neurosurgery, Pittsburgh, Pennsylvania, USA.

Objective: The goal of this study was to assess the indications of revision for vagal nerve stimulation at a single institution in an adult population with drug-resistant epilepsy.

Methods: This was a retrospective review of a prospectively collected database who underwent vagal nerve stimulator implantation for drug-resistant epilepsy during 1992-2017. Patients receiving vagal nerve stimulation (VNS) implants were monitored throughout their perioperative and postoperative course and were classified according to type of seizure at the time of diagnosis and indications for VNS revision. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18788750183202
Publisher Site
http://dx.doi.org/10.1016/j.wneu.2018.09.008DOI Listing
December 2018
9 Reads

[Transional syndrome: from West to Lennox-Gastaut syndromes].

Medicina (B Aires) 2018;78 Suppl 2:2-5

Universidad Autónoma de Aguascalientes, México. E-mail:

West syndrome or infantile spasms is an epileptic encephalopathy, classified as generalized epilepsies and syndromes. There are multiple reports of the evolution from West to Lennox-Gastaut syndrome of 25 up to 60%, without a specific cause is determined. It has been reported that they may be only an epileptic entity age dependent that it would be in relation to the degree of brain immaturity. Read More

View Article

Download full-text PDF

Source
March 2019
2 Reads

Cannabis for the Treatment of Epilepsy: an Update.

Curr Neurol Neurosci Rep 2018 Sep 8;18(11):73. Epub 2018 Sep 8.

Department of Neurology, University of Alabama at Birmingham Epilepsy Center, Birmingham, AL, USA.

Purpose Of Review: For millennia, there has been interest in the use of cannabis for the treatment of epilepsy. However, it is only recently that appropriately powered controlled studies have been completed. In this review, we present an update on the research investigating the use of cannabidiol (CBD), a non-psychoactive component of cannabis, in the treatment of epilepsy. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11910-018-0882-y
Publisher Site
http://dx.doi.org/10.1007/s11910-018-0882-yDOI Listing
September 2018
22 Reads